71 related articles for article (PubMed ID: 20205099)
1. Bone mineral density and metabolism in levothyroxine-treated adolescent girls with euthyroid diffuse goiter.
Matusik P; Małecka-Tendera E; Franek E; Januszek-Trzciakowska A
Endokrynol Pol; 2010; 61(1):14-9. PubMed ID: 20205099
[TBL] [Abstract][Full Text] [Related]
2. [The bone mineral density and the markers of the osseous circle in children with non-toxic parenchymatous or nodular goiter long-time treated with L-thyroxine].
Zak T; Golenko A; B Wasikowa R; Jedrzejuk D; Noczyńska A
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(1):13-7. PubMed ID: 15850533
[TBL] [Abstract][Full Text] [Related]
3. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density and metabolism in children treated with L-thyroxine.
Tümer L; Hasanoğlu A; Cinaz P; Bideci A
J Pediatr Endocrinol Metab; 1999; 12(4):519-23. PubMed ID: 10417967
[TBL] [Abstract][Full Text] [Related]
5. Thyroid hormone treatment aiming at reduced, but not suppressed, serum thyroid-stimulating hormone levels in nontoxic goitre: effects on bone metabolism amongst premenopausal women.
Knudsen N; Faber J; Sierbaek-Nielsen A; Vadstrup S; Sørensen HA; Hegedüs L
J Intern Med; 1998 Feb; 243(2):149-54. PubMed ID: 9566644
[TBL] [Abstract][Full Text] [Related]
6. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
Appetecchia M
Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
[TBL] [Abstract][Full Text] [Related]
7. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
Marcocci C; Golia F; Vignali E; Pinchera A
J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
[TBL] [Abstract][Full Text] [Related]
8. Bone metabolism in premenopausal women with nontoxic goiter and reduced serum thyrotropin levels.
Faber J; Overgaard K; Jarløv AE; Christiansen C
Thyroidology; 1994 Apr; 6(1):27-32. PubMed ID: 7536445
[TBL] [Abstract][Full Text] [Related]
9. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
Marcocci C; Golia F; Bruno-Bossio G; Vignali E; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
[TBL] [Abstract][Full Text] [Related]
10. Effect of thyroxine therapy on bone metabolism in substituted hypothyroid patients with normal or suppressed levels of TSH.
Gam AN; Jensen GF; Hasselstrøm K; Olsen M; Nielsen KS
J Endocrinol Invest; 1991 Jun; 14(6):451-5. PubMed ID: 1774441
[TBL] [Abstract][Full Text] [Related]
11. Reduced forearm bone mineral content and biochemical evidence of increased bone turnover in women with euthyroid goitre treated with thyroid hormone.
Taelman P; Kaufman JM; Janssens X; Vandecauter H; Vermeulen A
Clin Endocrinol (Oxf); 1990 Jul; 33(1):107-17. PubMed ID: 2401091
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
13. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism.
Pantazi H; Papapetrou PD
J Clin Endocrinol Metab; 2000 Mar; 85(3):1099-106. PubMed ID: 10720046
[TBL] [Abstract][Full Text] [Related]
14. [The effects of levothyroxine replacement therapy on bone and mineral metabolism in patients with hypothyroidism].
Chai R; Ye Z; Zhan Z; Liu W; Yu M; Liu Y
Zhonghua Nei Ke Za Zhi; 1999 Jan; 38(1):18-21. PubMed ID: 11798620
[TBL] [Abstract][Full Text] [Related]
15. Effects of suppressive doses of levothyroxine treatment on sex-hormone-binding globulin and bone metabolism.
Lecomte P; Lecureuil N; Osorio-Salazar C; Lecureuil M; Valat C
Thyroid; 1995 Feb; 5(1):19-23. PubMed ID: 7787428
[TBL] [Abstract][Full Text] [Related]
16. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women.
Uretmen S; Gol M; Cimrin D; Irmak E
Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):67-71. PubMed ID: 16051419
[TBL] [Abstract][Full Text] [Related]
17. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
18. Effects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort study.
Schneider R; Schneider M; Reiners C; Schneider P
J Clin Endocrinol Metab; 2012 Nov; 97(11):3926-34. PubMed ID: 22977269
[TBL] [Abstract][Full Text] [Related]
19. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
[TBL] [Abstract][Full Text] [Related]
20. Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy.
Langdahl BL; Loft AG; Eriksen EF; Mosekilde L; Charles P
Thyroid; 1996 Jun; 6(3):161-8. PubMed ID: 8837321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
